**ASX Release** **10 August 2026**
**ASX Code: MEM**

# PIVOTAL FELIX™ STUDY RECEIVES FIRST SCIENTIFIC PRESENTATION AT FSANZ 2026

**Highlights**

- **Results from the pivotal Felix™ clinical study were presented to a scientific audience for the first time at FSANZ 2026 in Canberra on 9 August 2026.**
- **The study involved 103 couples undergoing ICSI across 10 Monash IVF Group centres.**
- **Felix™ achieved a significantly higher Embryo Utilisation Rate of 58.8% compared with 49.1% for density gradient centrifugation (p=0.022).**
- **100% of clinicians preferred Felix process to Density Gradient Centrifugation (DGC)**
- **The study formed part of the clinical evidence supporting Felix™ achieving CE Mark certification.**
  **Felix™ now has regulatory access across Europe, Australia and the United Kingdom, with more than A$3 million in contracted minimum revenue secured during FY2026 and a subsequent A$350,000 agreement in Poland.**
- **Monash IVF Group has progressed from pivotal clinical trial partner to commercial partner under a 12-month exclusive national supply agreement.**

Memphasys Limited (ASX: MEM) ("Memphasys" or "the Company") is pleased to advise that the results of its pivotal Felix™ clinical study were presented to a scientific audience for the first time at the Fertility Society of Australia and New Zealand 2026 Annual Conference ("FSANZ 2026").

A/Prof Hassan Bakos, Memphasys Director, Clinical Partnerships & Growth, presented the findings at the National Convention Centre in Canberra on Sunday, 9 August 2026.

The study results were previously announced to the ASX on 24 March 2025. Their presentation at FSANZ 2026 represents the first formal presentation of the findings to a major scientific and clinical audience.

The presentation was titled:

*"The Felix™ System generates significantly higher embryo utilisation rates than density gradient centrifugation and comparable rates to swim-up: A multi-centre prospective randomized sibling oocyte trial."*

## Clinical results

The registered, multi-centre, blinded, randomised sibling oocyte study involved 103 couples undergoing intracytoplasmic sperm injection ("ICSI") across 10 Monash IVF Group centres.

The study compared sperm selected using Felix™ with two commonly used preparation methods: density gradient centrifugation ("DGC") and swim-up ("SU").

The primary outcome was Embryo Utilisation Rate ("EUR"), being the proportion of embryos available for transfer or cryopreservation.

**Memphasys Limited**
Level 1, 34-36 Richmond Road
Homebush West, NSW 2140

**Contact Details**
P +612 8415 7300

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556

The study found:

- Felix™ achieved a combined EUR of 58.8%, compared with 49.1% for DGC. The difference was statistically significant (p=0.022), demonstrating superiority for the study's primary outcome; and
- Felix™ achieved a combined EUR of 43.7%, compared with 42.7% for SU, demonstrating non-inferiority.
- 100% of clinicians preferred Felix process to Density Gradient Centrifugation. (DGC) with 60% preferring Felix compared to Swim-up

**Regulatory and commercial significance**

The study formed part of the clinical evidence supporting Felix™ achieving CE Mark certification under the European Union Medical Device Regulation in December 2025.

Felix™ is now:

- CE Mark certified, providing commercial access across the European Economic Area;
- included on the Australian Register of Therapeutic Goods (TGA approved); and
- registered with the UK Medicines and Healthcare products Regulatory Agency.

During FY2026, Memphasys secured more than A$3 million in contracted minimum revenue over multiple years, exceeding its stated A$2 million corporate objective.

The Company also recently announced it entered into an exclusive commercialisation agreement in Poland with a minimum contracted value of approximately A$350,000 over two years.

The Company now has commercial agreements, sales or active evaluations across Australia, Europe, the United Kingdom, the Middle East and North Africa, India, Japan and Southeast Asia.

The presentation provides Memphasys and its commercial partners with additional clinical evidence to support engagement with fertility clinics, embryologists and laboratory decision-makers as existing agreements progress towards product adoption and recurring cartridge orders.

**Monash IVF relationship**

The study was conducted as part of a scientific and clinical collaboration between Memphasys and Monash IVF Group spanning more than a decade.

In June 2026, this relationship progressed from clinical collaboration to commercial deployment when Memphasys entered into a 12-month exclusive national supply agreement with Monash IVF Group for Felix™ in Australia.

The agreement is currently in its initial three-month rollout phase across two Monash IVF sites. Successful completion of this phase will trigger the full 12-month supply term and provide a pathway for deployment across Monash IVF Group's Australian network of 22 clinics.

**Memphasys Non-Executive Chairman David Tasker said:**

"This first scientific presentation of the pivotal study results represents another important milestone in the commercial development of Felix™.

"The study generated important clinical evidence that supported Felix™ achieving CE Mark certification and demonstrated a significantly higher Embryo Utilisation Rate than density gradient centrifugation.

"Memphasys has since secured regulatory access across Europe, Australia and the United Kingdom, more than A$3 million in contracted minimum revenue during FY2026, and a further A$350,000 agreement in Poland.

“The presentation gives our commercial partners additional evidence to support clinic engagement as we work to convert regulatory access and contracted agreements into adoption and recurring cartridge revenue.

“Our relationship with Monash IVF Group has progressed from a decade-long scientific collaboration and pivotal clinical trial to our largest Felix™ commercial agreement, providing a model we are seeking to replicate internationally.”

**A/Prof Hassan Bakos added:**

“Presenting these findings at FSANZ enabled us to share the clinical evidence supporting Felix™ directly with leading fertility clinicians, embryologists and researchers.

“The results demonstrated that Felix™ achieved a significantly higher Embryo Utilisation Rate than density gradient centrifugation and a comparable rate to swim-up.”

A/Prof Bakos will also chair the FSANZ 2026 session “Evolving Standards and Innovations in Male Fertility Care” on Tuesday, 11 August 2026.

**Authorised by the Board of Memphasys Limited.**

**Ends**

For further information, please contact:

**Colin Jacoby**
Chapter One Advisors
T: +61 433 112 936
E: cjacoby@chapteroneadvisors.com.au

**About Memphasys**

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys’ commercial strategy is focused on building contracted and recurring sales through direct and distribution-led channels, scaling production to support commercial growth and establishing Felix™ as a new global standard in sperm preparation for assisted reproductive technology procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

**Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Memphasys’ current expectations, estimates and projections about the industry in which Memphasys operates, and its beliefs and assumptions.

Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties and are not guarantees of future performance. Memphasys cautions shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Memphasys only as of the date of this release.